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Abstract
Background: HIV exposed seronegative (HESN) women represent the population most in need of a prophylactic antiviral
strategy. Mucosal cationic polypeptides can potentially be regulated for this purpose and we here aimed to determine their
endogenous expression and HIV neutralizing activity in genital secretions of women at risk of HIV infection.
Methodology/Principal Findings: Cervicovaginal secretions (CVS) of Kenyan women in HIV-serodiscordant relationships
(HESN, n=164; HIV seropositive, n=60) and low-risk controls (n=72) were assessed for the cationic polypeptides HNP1–3,
LL-37 and SLPI by ELISA and for HIV neutralizing activity by a PBMC-based assay using an HIV primary isolate. Median levels
of HNP1–3 and LL-37 in CVS were similar across study groups. Neither HSV-2 serostatus, nor presence of bacterial vaginosis,
correlated with levels of HNP1–3 or LL-37 in the HESN women. However, an association with their partner’s viral load was
observed. High viral load (.10,000 HIV RNA copies/ml plasma) correlated with higher levels of HNP1–3 and LL-37 (p=0.04
and 0.03, respectively). SLPI was most abundant in the low-risk group and did not correlate with male partner’s viral load in
the HESN women. HIV neutralizing activity was found in CVS of all study groups. In experimental studies, selective depletion
of cationic polypeptides from CVS rendered the remaining CVS fraction non-neutralizing, whereas the cationic polypeptide
fraction retained the activity. Furthermore, recombinant HNP1–3 and LL-37 could induce neutralizing activity when added
to CVS lacking intrinsic activity.
Conclusions/Significance: These findings show that CVS from HESN, low-risk, and HIV seropositive women contain HIV
neutralizing activity. Although several innate immune proteins, including HNP1–3 and LL-37, contribute to this activity these
molecules can also have inflammatory properties. This balance is influenced by hormonal and environmental factors and in
the present HIV serodiscordant couple cohort study we show that a partner’s viral load is associated with levels of such
molecules.
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Mucosal surfaces of the female genital tract are portals for
sexual transmission of microbes and viruses, and cationic
antimicrobial polypeptides are the principal effector molecules of
mucosal innate immunity. Together with other innate immune
cells and molecules, as well as physical and chemical barriers
(mucus, low pH, epithelial integrity), these antimicrobials normally
contribute to an efficient barrier against low dose HIV exposure
during sexual intercourse with an HIV infected partner [1,2].
Innate immune molecules may thus contribute to the natural
immune defense against HIV in genital tract secretions. Prior
innate immunity studies focused on HIV-infected and uninfected
women from low HIV-endemic regions [3,4,5] and highly HIV
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polypeptides are secreted from immune and epithelial cells into
cervicovaginal secretions (CVS) and can potentially be regulated
selectively by vaccines and microbicides against mucosal infec-
tions. The desired modulation of innate immune responses must,
however, be balanced to avoid stimulation of immunopathological
effects.
Several cationic polypeptides such as human neutrophil
peptides 1–3 (HNP1–3), LL-37 and secretory leukocyte protease
inhibitor (SLPI) have been shown to possess HIV inhibitory
activity in vitro and are present at detectable levels in CVS
(reviewed by [11]). HNP1–3 are members of the human alpha-
defensin family and inhibit HIV replication through intracellular
interference with protein kinase C activity and direct inactivation
of HIV virions [12,13]. LL-37 belongs to the family of
cathelicidins and mediates HIV inhibitory activity [14], although
the antiviral mechanism is not clear. SLPI is a serine protease
inhibitor that exerts one of its anti-HIV effects by binding to
annexin II and impairing annexin II-mediated stabilization of
fusion [15,16].
Each of these synergistically acting molecules can have
multifaceted roles influenced by the immunologic, hormonal,
and microbial status of the genital mucosal surface of sexually
active individuals. In a previous study, we showed that cationic
polypeptides were required for anti-HIV activity of human vaginal
fluid from healthy women at low risk of sexual HIV exposure [5].
We now extend these studies and explore the anti-HIV activity of
human CVS from Kenyan HIV infected and uninfected women
with differing risks of HIV infection. The HIV exposed
seronegative (HESN) women, who represent the population most
in need of a prophylactic vaccine or microbicide compound, have
a high prevalence of herpes simplex virus type 2 (HSV-2), bacterial
vaginosis (BV) and other factors influencing the mucosal
environment and innate immune composition.
Materials and Methods
Study population
During the years 2007–2010, HIV serodiscordant (n=469)
couples were enrolled in a prospective cohort study in Nairobi,
Kenya and followed for up to 2 years with visits every 3 months
[17]. Eligible couples reported sexual intercourse with each other
$3 times in the 3 months prior to screening, planned to remain
together in Nairobi for the two-year duration of the study, female
partners could not be pregnant at enrollment, and the HIV-
positive partners did not have clinical AIDS (WHO stage IV) or a
history of taking antiretroviral treatment. Additionally, for the
present sub-study, HIV seropositive and HIV seronegative women
were selected from this larger cohort based on sample availability.
Women were excluded if they showed evidence of an active
sexually transmitted infection (STI) on genital examination.
During the same time period, couples testing concordantly
negative for HIV were recruited from the same voluntary
counseling and testing (VCT) centers as the discordant couples
as a control population. Concordant negative couples also
reported having sex with their partner $3 times in the 3 months
prior to screening. A subset of women from these negative control
couples was selected based on sample availability and assigned to
the ‘Low-risk’ study group. The study protocols were approved by
institutional review boards at the Kenyatta National Hospital
(Nairobi, Kenya), the University of Washington (Seattle, USA) and
the Karolinska Institutet (Stockholm, Sweden). Written consent
was obtained from all study participants.
Sample collection
For the present study, CVS were collected from these women at
the time of study enrollment and a questionnaire was administered
by a nurse-counselor that included sociodemographic data and
sexual/reproductive history. A physical examination, including a
genital examination, was performed. CVS were collected by
rotating a cotton swab 360u in the outer part of the endocervix and
by rotating a different swab across the vaginal wall. Both swabs
were placed in the same tube containing 5 ml sterile phosphate
buffered saline (PBS), which was immediately placed on ice. The
samples were then transported from the clinic to the laboratory on
ice and centrifuged at 800 g for 10 minutes at 4uC. Supernatants
were separated from the cell pellet, aliquoted into 4 cryovials, each
containing 1 ml fluid, and stored at 280uC. CVS from healthy
Swedish low-risk HIV seronegative women were collected and
stored according to the same procedure and were used as internal
controls for the in vitro experiments.
Study subjects and sample collection for the in vitro
experiments
For cationic polypeptide depletion experiments, a more
concentrated CVS sample was required. HIV seronegative
women, without any clinical or laboratory signs of STIs
(chlamydia, gonorrhea, syphilis, or candida) or BV, were recruited
from the Maternal and Child Health Clinic in Pumwani, Nairobi.
One cotton swab soaked in mucus from the cervico-vaginal tract
was placed in 0.5 ml of saline and placed on ice. The vials were
transported to the laboratory where the samples were stored in
280uC.
HIV testing and STI screening
HIV rapid testing was conducted in the Study Clinic using two
commercial kits (DetermineH HIV–1/2 Rapid Test, Abbott
Laboratories, Abbott Park, IL; Bioline
TM Recombigen HIV Test,
Standard Diagnostic Inc.). Positive or indeterminate results were
confirmed with HIV-1 enzyme-linked immunosorbent assay
(ELISA) using the VironostikaH HIV Uni-Form II Ag/Ab ELISA
kit (Biomerioux Laboratories, the Netherlands) in the University of
Nairobi’s Obstetrics/Gynecology laboratory. Plasma HIV-1 RNA
viral load in HIV-seropositive partners was quantified using the
Gen-Probe Transcription Mediated Amplification (TMA) assay
[18]. HSV-2 serostatus was determined using the HerpeSelect IgG
ELISA kit (Focus Technologies, Cyprus, CA) using a cutoff of 3.5
to improve specificity. Syphilis testing was performed in University
of Nairobi’s Medical Microbiology Laboratory using the rapid
plasma regain (RPR) Card Test Macro-Vue kit (Becton Dickinson,
Franklin Lakes, NJ), with reactive RPR tests confirmed with
TPHA, a treponemal-specific indirect hemagglutination test
(RANDOX Laboratories, Crumlin, UK). Vaginal Gram test was
performed and BV was defined as a Nugent score of 7–10.
Measurement of prostate-specific antigen (PSA)
Prostate-specific antigen (PSA) levels in CVS were measured by
an external accredited laboratory (Aleris Medilab, Ta ¨by, Sweden)
using the ARCHITECT Total PSA assay (Abbott Ireland
Diagnostics Division, Dublin, Ireland), a chemiluminescent
microparticle immunoassay. The PSA levels in the CVS are
reported as measured in the original 5 ml dilution. A level above
1 mg PSA/mL CVS were defined as a positive result [19].
HNP1–3, LL-37 and SLPI quantification
Commercial ELISA kits were used, according to the manufac-
turers protocols, to quantify the immune molecules of interest at
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(1:10) (both Hycult Biotechnology, Uden, the Netherlands), and
SLPI (1:100-1:1000) (RD Systems Europe Ltd, Abingdon Oxon,
UK). The CVS levels of the factors are reported as measured in
the original 5 ml dilution.
HIV neutralization assay
HIV neutralization assays were performed according to a
predefined protocol and neutralization cut off [20]. Prior to this
assay, the IgA1 fraction of the CVS was removed by adding 800 ml
of undiluted CVS to 400 ml of jacalin-agarose beads (Immunkemi,
Stockholm, Sweden) then mixing for 2 h at +4uC followed by
centrifugation (2000 rpm, 5 min, 4uC). The unbound (IgA1-
depleted) fraction was collected and stored at 280uC until use. For
the HIV neutralizing assay we used an R5 tropic primary isolate of
HIV subtype A (isolate 92UG037; AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH). To account
for variations in TCID50 depending on PBMC donor variability,
three viral dilutions were used in each assay. Duplicate wells of
75 ml of each virus dilution and 75 ml of each sample fraction
(undiluted) were incubated for 1 h at 37uC followed by addition of
a mixture of 1610
5 PHA-P-stimulated PBMC from two donors.
After 24 h incubation at 37uC, the cells were centrifuged;
unbound virus was washed away, and 200 ml of fresh medium
were added to each well. On day 3, 120 ml of medium was
discarded and replaced with new medium, after which day 6
supernatants were collected for analysis of virus production with a
p24 antigen ELISA (Vironostika HIV-1 Antigen; Electra-Box
Diagnostica AB, Stockholm, Sweden). Neutralization was defined
as a $67% reduction of p24 antigen in the supernatant as
compared with p24 antigen content when the virus isolate was
incubated in the presence of a standard pool of Swedish HIV
seronegative samples.
Selective depletion of cationic polypeptides from CVS
Carboxymethyl (CM) weak cation exchange resin (Bio-Rad)
was used to deplete cationic polypeptides from vaginal fluid [5].
The CM resin was pre-equilibrated by washing 6 times with a
buffer resembling vaginal fluid in electrolyte composition
(60 mM NaCl, 20 mM potassium phosphate, pH 6, [4]). Equal
volumes of CVS from four to six HIV seronegative donors were
centrifuged and pooled before the extraction of cationic
polypeptides. From each pool, 0.5 mL CVS was reserved and
stored at 280uC as ‘‘unprocessed CVS’’. The remaining volume
from each pool was CM-extracted by mixing with equilibrated
CM resin at 4uC overnight in an end-over-end tumbler.
Centrifugation (15,0006g, 4uC, 3 min) enabled collection of
the CM-depleted CVS supernatant, which was then cleared of
residual resin by additional centrifugations and stored at
280uC. The CM resin sediment was washed 5 times with
25 mM ammonium acetate, pH7, and then cationic proteins
were extracted by incubating the washed resin with 5% acetic
acid in a tumbler at 4uC. Extracted proteins were collected and
stored at 280uC after 2 h, and the resin was extracted a second
time by incubation with more acetic acid overnight in a tumbler
at 4uC .T h ef i r s ta n ds e c o n dc a t i o n i ce x t r a c t sw e r ep o o l e d ,
clarified of residual resin, concentrated by vacuum centrifuga-
tion, and restored to the original volume. All samples were
stored at 280uCu n t i lu s e .
Recombinant innate factors and HIV neutralization
Recombinant SLPI (RD Systems Europe Ltd, Abingdon Oxon,
UK), LL37 and HNP1–3 (both Hycult Biotechnology, Uden, the
Netherlands) were added in serial dilutions to IgA-depleted CVS
samples from low-risk HIV seronegative women who were selected
based on lack of intrinsic neutralizing capacity. The recombinant
peptides were incubated with the CVS samples for 1 hr. Following
this pre-incubation, the samples were tested in the HIV
neutralization assay as described above except for the use of
another HIV isolate of the same HIV subtype (subtype A: RW/
92/024; AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH).
Statistical analysis
Statistical comparisons of the immune parameters between
groups were performed by using the Mann-Whitney U test, and
calculations were performed by using the GraphPad Prism 5
software (GraphPad Software, Inc., San Diego, CA, USA) and
STATA version 11.2/IC (College Station, TX, USA). A p-value of
,0.05 was considered statistically significant.
Owing to lack of sufficient volume of some CVS samples, not all
300 samples were assessed for all parameters in the following
sections. However, the number of samples assessed in each case is
presented in the table and figure legends.
Because a partner’s viral load of 10,000 or greater has been
shown as an epidemiologic determinant for higher transmission
risk in this geographical setting [21], this content was selected as a
cut-off for dividing the HESN women into two groups: HESN
women whose partner’s viral load was higher than 10,000 versus
HESN women whose partner’s viral load was lower than 10,000.
Results
Demographic data and levels of antiviral cationic
polypeptides in CVS samples
In the present study, CVS samples were assessed from a total of
296 study participants: HIV seropositive (HIV pos, n=60) and
HIV seronegative (HESN, n=164) women representing the
serodiscordant couple cohort as well as HIV seronegative (Low-
risk, n=72) women living with a seroconcordant HIV-negative
male partner. Demographic data and sexual risk-taking profiles of
the study subjects are outlined in Table 1. While number of life
time partners, history of STIs, presence of BV and male partner
circumcision status were comparable, the parameters age,
presence of PSA, and HSV-2 seropositivity differed between the
groups.
The most abundant peptide among the ones investigated
(HNP1–3, LL-37, SLPI) in all three study groups was HNP1–3,
with comparable median levels for the HIV-positive, HESN and
low-risk groups (median values 240, 185 and 205 ng/ml,
respectively) (Figure 1). Also, levels of LL-37 were comparable
between the groups (median values 12, 8 and 5 ng/ml,
respectively). However, less SLPI was present in the HIV positive
group than in the other two groups (median values 37, 64 and
106 ng/ml, respectively) (HIV pos vs HESN: p=0.013; HIV pos
vs Low-risk: p,0.001); likewise, the HESN group contained less
SLPI than the low-risk group (HESN vs Low-risk p=0.005)
(Figure 1).
Levels of cationic polypeptides in relation to partner’s
viral load, HSV-2 serostatus, and presence of BV
We examined several mucosal factors that could potentially
influence the levels of cationic polypeptides. First, in the HESN
group, partner’s viral load (greater than or less than 10,000 HIV
RNA copies/ml plasma) was compared to levels of the individual
peptides (Figure 2). HESN women whose partner’s viral load was
higher than 10,000 (n=127) had significantly higher levels of
HNP1–3 and LL37 than HESN women whose partner’s viral load
HIV-Neutralizing Factors in Genital Secretions
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p=0.036; LL-37: 9 vs 4 ng/ml, p=0.028). Levels of SLPI were
however not affected by high or low levels of partner’s viral load.
We next assessed the association of HSV-2 serostatus and
presence of BV with levels of the peptides in all study groups. HIV
positive women who were co-infected with HSV-2 had signifi-
cantly higher levels of LL-37 than those who were HSV-2
seronegative (16 vs 5 ng/ml, p=0.016). Among the HESNs, lower
levels of SLPI were observed for the HSV-2 seropositive as
compared with the HSV-2 seronegative women (55 vs 99 ng/ml,
p=0.030) (Figure 3a–c). For HESN and low-risk controls, no
significant differences were seen when comparing the influence of
BV on peptide levels. Presence of BV was however associated with
higher levels of SLPI in HIV positive women (median levels of
SLPI in BV positive vs BV negative women: 42 vs 24 ng/ml,
p=0.035) (Figure 3d–f).





Characteristics of female study subjects Median or number (interquartile range or %)
Age (years) 28 (24–31) 29 (25–35) 25 (22–30)
Lifetime partners 3 (2–4) 3 (2–3) 3 (2–3)
History of STIs
d 18 (33%) 34 (22%) 17 (24%)
Presence of PSA
e 5 (12%) 15 (10%) 23 (33%)
Presence of BV 6 (10%) 22 (14%) 14 (25%)
HSV-2 seropositivity 32 (53%) 111 (68%) 22 (33%)
Characteristics of male partners
Age (years) 32 (28–36) 36 (32–43)
Lifetime partners 5 (3–10) 5 (4–9)
History of STIs
d 18 (35%) 77 (48%)
Circumcision 46 (78%) 116 (71%)
HSV-2 seropositivity 20 (33%) 109 (66%)
CD4 cell count (cells per ul/100) 355 (237–517)
Viral load (log10 copies/ml) 4.76 (4.07–5.34)
Characteristics of couples
Sex act with study partner in last 6 months6 (3–10) 4.5 (2–8)
Years living together 3 (2–6) 6 (2–10)
a–cHIV seropositive (HIV pos) and HIV seronegative (HESN) women and their HIV serodiscordant male partners were evaluated for demographic data and sexual risk-
taking profiles. In addition, HIV seronegative women (Low-risk) living with an HIV seronegative male partner were included (male participants in the Low-risk study
group were not assessed for demographic parameters). In total, complete demographic data sets were available from 288 of the 300 women whose CVS samples
were assessed for immunological parameters.
dSTIs: sexually transmitted infections.
ePSA: Prostate-specific antigen (.1 ug/ml of CVS) as a sign of recent unprotected sexual intercourse.
doi:10.1371/journal.pone.0031996.t001
Figure 1. Levels of cationic polypeptides in the study groups. CVS were collected from HIV seropositive women (HIV pos) as well as from HIV
seronegative women living with either an HIV infected man (HESN) or an HIV uninfected man (Low-risk). Levels of the respective cationic polypeptide
for the different study groups are shown. (a) HNP1–3 (HIV-pos n=52, HESN n=163, low-risk n=64), (b) LL-37 (HIV-pos n=52, HESN n=162, low-risk
n=63) and (c) SLPI (HIV-pos n=60, HESN n=86, low-risk n=41). Assay detection level was 0.16 ng/ml for HNP1–3, 0.14 for LL-37 and 0.06 for SLPI,
results below cut-off were assigned the value y=0,1. Solid line indicates median concentration, whiskers indicate 5–95 percentile. *p,0.05.
doi:10.1371/journal.pone.0031996.g001
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absence of PSA in the CVS samples
To evaluate the influence of seminal contamination in the CVS,
samples were assessed for presence of PSA (.1 mg/ml) and then
compared for levels of cationic polypeptides. PSA was found in
33% of the CVS samples representing the low-risk group followed
by 12% in the HIV positive group and 10% in the HESN group
(Table 1). Assessing all study groups together, no statistically
significant differences were seen between PSA positive and PSA
negative CVS samples for levels of HNP1–3 (median levels: 160 vs
205 ng/ml, p=0.19). Levels of LL-37 were however significantly
lower among the PSA positive versus the PSA negative CVS
samples (median levels 3 vs 7 ng/ml, p=0.015), whereas levels of
SLPI were significantly higher among the PSA positive versus the
PSA negative CVS samples (median levels: 101 vs 59 ng/ml,
p=0.029). Reanalysing the data presented in Figure 1 by
excluding the PSA-positive samples did not affect the median
values of the peptide levels significantly (data not shown).
However, for LL-37, exclusion of PSA-positive samples resulted
in a significant difference between the HIV-positive and low-risk
groups (13 vs 5 ng/ml, p=0.04).
Levels of cationic peptides in relation to HIV
neutralization capacity
As previously shown [22], the IgA fraction of whole CVS could
potentially neutralize HIV in our PBMC-based neutralizing assay
in a proportion of the present samples. We therefore depleted IgA
from whole CVS prior to assessment of neutralizing capacity of the
samples to avoid the influence of this factor. In 27 of 152 (18%)
IgA-depleted samples from the HESN women, HIV was
neutralized. In the low-risk group, the corresponding proportion
was 17 of 63 (27%) and in the HIV positive group 17 of 46 (37%).
When excluding PSA-positive samples from the analysis the
corresponding percentages were 19%, 30% and 30% for the
HESN, low-risk and HIV positive group, respectively.
Samples from the study groups were then divided based on the
presence/absence of neutralization capacity and within each study
group and comparison was made between neutralizing and non-
neutralizing samples in terms of their levels of each peptide
(Figure 4). No statistically significant differences were seen between
neutralizing and non-neutralizing samples for levels of HNP1–3 or
LL-37 in any of the study groups. In the HESN group, samples
that could neutralize HIV had significantly lower levels of SLPI
(31 ng/ml vs 76 ng/ml; p=0.02).
Cationic polypeptides contribute substantially to the
HIV-neutralizing activity of CVS from HIV seronegative
individuals
In this set of experiments, we explored the HIV-neutralizing
activity of the cationic polypeptide components of CVS from HIV
seronegative women. A total of 14 CVS samples were selected for
the presence of intrinsic HIV neutralizing activity and pooled into
three groups to reach sufficient volume for the following
experiments (Figure 5). First, the cationic polypeptides were
selectively removed from the CVS pools while sparing the
concentrations of remaining proteins and electrolytes. The
complete removal of cationic polypeptides was confirmed by
AU-PAGE for all pools (data not shown). The cationic polypeptide
fractions were then tested for HIV neutralizing activity, and each
fraction had activity equivalent to that of the whole pool (Figure 5).
The remaining peptide-depleted CVS samples had no HIV
neutralizing activity. Thus, the majority of the functional activity
seems to be mediated by the cationic polypeptide fraction.
Recombinant cationic polypeptides can augment the
intrinsic HIV-neutralizing activity of CVS from HIV low-risk
women
Next we studied whether adding individual recombinant
cationic polypeptides to CVS could induce HIV neutralizing
activity. Theoretically, the added peptides would act synergistically
with other innate immune factors naturally present in CVS. For
these experiments, CVS from HIV seronegative women lacking
intrinsic HIV neutralizing activity were selected and the HIV
neutralizing assay was adapted to establish the ratio between
peptide+CVS versus medium+CVS. SLPI as well as recombinant
HNP1–3 and LL-37 were evaluated in three independent
experiments. As a result, both HNP1–3 and LL-37 induced a
two to six-fold increase of HIV inhibiting activity when assessed at
about 10–50 times the physiological concentrations, whereas the
effect of SLPI was only marginal (Figure 6). At physiological
concentrations (as determined within the present study cohort), no
effect was seen for any of the peptides.
Discussion
We document here the presence of cationic polypeptides and
intrinsic HIV neutralizing activity in CVS of Kenyan women who
are HIV infected, HESN, and HIV-uninfected low risk. The three
cationic polypeptides HNP1–3, LL-37 and SLPI were selected for
assessment because they were previously shown to be important
mediators of HIV neutralization in vitro, and because they are
detectable in cervicovaginal lavage from healthy women (reviewed
in [11]). Although presence of HIV neutralizing activity did not
associate directly with individual levels of HNP1–3 or LL-37, it
was clearly correlated with the whole cationic polypeptide fraction
of CVS. This correlation was shown in vitro by selectively depleting
Figure 2. Correlations of partner’s viral load with levels of
cationic polypeptides in the HESN group of women. Expression
of cationic polypeptides in CVS from HIV seronegative women in a
serodiscordant relationship (the HESN group) was stratified for partner’s
viral load (VL, HIV RNA copies/ml plasma) at time of sample collection.
ELISA-data of levels of HNP1–3 (VL,10.000 n=37, VL.10.000 n=126),
LL-37 (VL,10.000 n=37, VL.10.000 n=125) and SLPI (VL,10.000
n=20, VL.10.000 n=66). Assay detection level was 0.16 ng/ml for
HNP1–3, 0.14 for LL-37 and 0.06 for SLPI, results below cut-off were
assigned the value y=0.1. Solid line indicates median concentration,
whiskers indicate 5–95 percentile. *p,0.05.
doi:10.1371/journal.pone.0031996.g002
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significantly reduced the functional activity. In another set of
experiments, human CVS lacking intrinsic HIV neutralizing
activity gained this function following addition of recombinant
HNP1–3 or LL-37, but only marginally from SLPI.
Detailed demographic data were collected from the study
participants. Despite being thoroughly counseled on sexual risk
behavior, signs of recent unprotected sexual intercourse as assessed
by measurement of PSA were documented in 10% of the HESN
women and in 12% of the HIV seropositive women. The
corresponding figure in the low risk women was 33%. Further-
more, none of the HIV infected partners of the HESN women
were on ARV treatment at enrollment; about two-thirds of the
partners had a plasma viral load above 10,000 HIV RNA copies
per ml, a threshold shown to correlate with a high risk of HIV
transmission in this setting [21]. When the HIV infected partners
were stratified into two groups according to viral load (more or less
than 10,000), significant associations were seen with cationic
polypeptide levels in the CVS of the corresponding HIV
uninfected partner; a partner’s viral load above 10,000 associated
with higher levels of HNP1–3 and LL-37, whereas no association
was seen for SLPI. Thus, although seminal fluid and plasma viral
load may not be directly correlated, sexual exposure to a high viral
load may have provoked a mucosal inflammatory response,
including the release of these peptides into the genital secretions.
Levels of the cationic polypeptides were also related to study
group, HSV-2 serostatus and presence of BV. Levels of both
HNP1–3 and LL-37 were similar when compared between study
groups, whereas SLPI levels were lowest in the HIV positive group
and highest in the low risk group. SLPI can be degraded by
endogenous proteases and by proteolytic activity of pathogenic
agents and, although not assessed here, HIV positive individuals
differ in many aspects with regard to the genital mucosal
environment that could account for the findings. HIV infected
individuals who were HSV-2 seropositive had higher levels of LL-
37 than their HSV-2-seronegative counterparts within the same
study group. In HESNs, levels of SLPI were lower for HSV-2
seropositive than HSV-2 seronegative individuals. Active HSV-2
infection and bacterial STIs have previously been shown to affect
levels of cationic polypeptides, including increased levels of LL-37
and HNP1–3 in Kenyan high risk women [9,10,23]. No
association between levels of LL-37 and HNP1–3 were seen when
the study groups were evaluated for the presence of BV which is in
agreement with our previous data [9]. In studies of a low risk
Figure 3. Correlations of HSV-2 serostatus and presence of BV with levels of cationic polypeptides in the study groups. CVS were
collected from HIV seropositive women (HIV pos) as well as from HIV seronegative women living with either an HIV infected man (HESN) or an HIV
uninfected man (Low-risk). Comparison of women with or without HSV-2 infection (HSV+/2): Levels of (a) HNP1–3 (HIV2 pos HSV2 n=23, HIV-pos
HSV+ n=29, HESN HSV2 n=52, HESN HSV+ n=110, low-risk HSV2 n=37, low-risk HSV+ n=22), (b) LL-37 (HIV-pos HSV2 n=24, HIV-pos HSV+ n=28,
HESN HSV2 n=52, HESN HSV+ n=109, low-risk HSV2 n=36, low-risk HSV+ n=22) and (c) SLPI (HIV-pos HSV2 n=28, HIV-pos HSV+ n=32, HESN
HSV2 n=28, HESN HSV+ n=58, low-risk HSV2 n=28, low-risk HSV+ n=9). Comparison of women with or without BV (BV+/2): (d) Expression of
HNP1–3 (HIV-pos BV2 n=47, HIVpos BV+ n=4, HESN BV2 n=138, HESN BV+ n=22, low-risk BV2 n=38, low-risk BV+ n=11). (e) Expression of LL-37
(HIV-pos BV2 n=46, HIV-pos BV+ n=5, HESN BV2 n=137, HESN BV+ n=22, low-risk BV2 n=38, low-risk BV+ n=11). (f) Expression of SLPI (HIV-pos
BV2 n=53, HIV-pos BV+ n=6, HESN BV2 n=71, HESN BV+ n=14, low-risk BV2 n=19, low-risk BV+ n=8). Assay detection level was 0.16 ng/ml for
HNP1–3, 0.14 for LL-37 and 0.06 for SLPI, results below cut-off were assigned the value y=0.1. Solid line indicates median concentration, whiskers
indicate 5–95 percentile. *p,0.05.
doi:10.1371/journal.pone.0031996.g003
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decreased levels of defensins and SLPI [11,24], and in the present
study we noted lower levels of SLPI in BV-positive HIV infected
women. Other causes of genital inflammation could also impact
levels of the cationic polypeptides but this was not further
evaluated due to their low prevalence in our selected study
population (3% were infected with trichomoniasis and only 1
(0.3%) subject was seropositive for syphilis, data not shown).
HIV inhibitory activities of mucosal fluids of low-risk HIV-
seronegative individuals have been reported and assigned to a
number of different innate molecules in addition to the ones
assessed in the present study [3,11,25]. Since IgA antibodies from
HESN and HIV infected individuals may mediate HIV neutral-
izing activity [22], these molecules were depleted from all CVS
samples prior to measurement of functional activity. In the present
study, 37% of the HIV positive, 18% of the HESN and 27% of the
low-risk women demonstrated HIV neutralizing activity as
assessed in IgA-depleted samples. The high percentage of HIV
neutralizing activity seen in the HIV infected group most likely
results from the presence of HIV IgG antibodies. Our experi-
mental results showing that depletion of cationic polypeptides
abolished the HIV neutralizing activity, and that the functional
activity remained in the cationic polypeptide fraction, imply a
potential role of these molecules as antiviral agents at local sites.
Together, the present results with CVS samples representing
Kenyan women at risk of HIV infection extends our previous
studies utilizing CVS collected from healthy women from a low
HIV endemic area [5]. In the latter study [5], we could restore
functional activity by adding back the whole cationic polypeptide
fraction to the depleted CVS sample, whereas individual
recombinant forms of the most prevalent peptides were not
sufficient. In the present study using another HIV neutralizing
assay, recombinant LL-37 and HNP1–3, but not SLPI, augmented
the functional activity at levels about 10 times that of their
Figure 5. Cationic polypeptides contribute substantially to the HIV-neutralizing activity of CVS from HIV seronegative women. The
HIV neutralizing activities of unprocessed CVS, cationic-depleted CVS and cationic polypeptides extracted from the CM resin (the cationic fraction); all
were tested individually for each pool of CVS samples. The concentrations of LL37 and HNP 1–3, respectively, in the different pools were: A: 4 and
30 ng/ml, B: 2 and 10 ng/ml, C: 2 and 10 ng/ml. The results shown are from one representative experiment using duplicate wells and two different
virus dilutions (median values 6SEM).
doi:10.1371/journal.pone.0031996.g005
Figure 4. Correlation of HIV neutralizing activity and levels of cationic polypeptides in the study groups. CVS were collected from HIV
seropositive women (HIV pos) as well as from HIV seronegative women living with either an HIV infected man (HESN) or an HIV uninfected man (Low-
risk). HIV neutralization capacity (NT) of IgA-depleted CVS: The study samples were sorted by whether neutralization occurred (NT) or not (no NT).
Levels of (a) HNP1–3 (HIV-pos no NT n=26, HIV-pos NT n=15, HESN no NT n=124, HESN NT n=27, low-risk no NT n=43, low-risk NT n=14), (b) LL-37
(HIV-pos no NT n=28, HIV-pos NT n=15, HESN no NT n=123, HESN NT n=27, low-risk no NT n=41, low-risk NT n=15) and (c) SLPI (HIV-pos no-NT
n=29, HIV-pos NT n=17, HESN no NT n=73, HESN NT n=12, low-risk no NT n=25, Ctrl NT n=11). Assay detection level was 0.16 ng/ml for HNP1–3,
0.14 for LL-37 and 0.06 for SLPI, results below cut-off were assigned the value y=0.1. Solid line indicates median concentration, whiskers indicate 5–
95 percentile. *p,0.05.
doi:10.1371/journal.pone.0031996.g004
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binant proteins can never be directly compared with that of
endogenous molecules.
Additional interactions and synergistic effects of the cationic
polypeptides may occur at the mucosal tissue level if the virus
penetrates beyond the cervical secretion. Indeed, molecules that
perform antimicrobial activity in human secretions may have a
counteractive effect in the genital mucosa and contribute to
inflammation and recruitment of immune cells that in turn could
be infected [26]. Studying the effect of innate immune factors in
mucosal fluids in their biological context is essential, since their
functions are heavily influenced by the physiological and chemical
milieu. Although HNP1–3 and LL37 have antiviral activity in vitro
they have been associated with an increased rate of HIV
acquisition in a cohort of high-risk sex workers [9]. The increased
levels of these factors most likely came from ongoing STIs;
consequently, the antiviral effect may have been overridden by
inflammation and target cell recruitment. Clearly, inflammatory
and antiviral properties are delicately balanced during the innate
immune response to HIV at mucosal sites.
Several important confounders must be considered in the
context of HESN individuals and assessment of mucosal immune
responses. Direct effects of sexual intercourse and secondary
immune effects of inflammation were here partly controlled for by
assessment of PSA and excluding subjects with ongoing STIs.
However, hormonal factors and other inflammatory conditions
influence the local mucosal environment [2,27]. Furthermore,
other types of assays measuring HIV inhibitory activity or the use
of other primary HIV-isolates may reveal important functional
activity in addition to the HIV neutralizing activity recorded here.
Levels of specific innate immune factors cannot be directly
associated with antiviral activity since their biological active form
may not be optimally measured by current assays and because
they also act in synergy with other innate molecules. Likewise,
when the cationic polypeptides where assessed in their recombi-
nant forms, their bioactivity may not exactly reflect the
physiological effect of the natural molecule or that of other
recombinant variants in previous studies.
Considerable attention has been directed to developing
microbicides for topical use to prevent sexual HIV transmission,
with promising results from recent clinical trials [28]. Although
antiretroviral drugs are the best candidates today, analogues of
innate immune molecules that reduce local inflammation and
provide an intrinsic HIV inhibitory capacity could be comple-
mentary. Characterization of baseline levels of endogenous
microbicides in relevant target populations is thus essential, since
synergistic activity between endogenous and exogenous microbi-
cide molecules may influence the HIV inhibitory effect. Indeed,
study populations representing different geographical regions and
with different HIV risk exposures vary in the composition of their
normal bacterial microflora, HSV-2 seropositivity and presence of
other STIs [29]. Because all these factors contribute to the
composition and levels of innate immune molecules, other
parameters of mucosal inflammation and ultimately HIV
susceptibility warrant examination and confirmation of their
beneficial management through pharmaceutical or immunologic
means.
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